Castration induces autoantibody and T cell responses that correlate with inferior outcomes in an androgen-dependent murine tumor model

International Journal of Cancer

Volumn 125, Issue 12, 2009, Pages 2871-2878

  Hahn, Sara ^a,b   Nesslinger, Nancy J ^b   Drapala, Robert J ^c   Bowden, Mary ^c   Rennie, Paul S ^c   Pai, Howard H ^b   Ludgate, Charles ^b   Nelson, Brad H ^a,b  

^a UNIVERSITY OF VICTORIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Autoantibody; Hormone therapy; Immune response; Prognosis; Prostate cancer; T lymphocyte; Tumor antigens; Tumor recurrence

Indexed keywords

ANDROGEN; ANTIGEN; AUTOANTIBODY; COMPLEMENTARY DNA; GAMMA INTERFERON; POLYADENYLIC ACID BINDING PROTEIN; POLYADENYLIC ACID BINDING PROTEIN NUCEAR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CANCER RECURRENCE; CASTRATION; CD3+ T LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSPOT ASSAY; HORMONAL THERAPY; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCREENING; SEROLOGY; T LYMPHOCYTE; TUMOR MODEL; TUMOR REGRESSION;

ANDROGENS; ANIMALS; AUTOANTIBODIES; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; POLY(A)-BINDING PROTEIN II; PROSTATIC NEOPLASMS; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 72449166655     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24673     Document Type: Article

References (46)

1. Hoeppner LH, Dubovsky JA, Dunphy EJ, McNeel DG. Humoral immune responses to testis antigens in sera from patients with prostate cancer. Cancer Immun 2006;6:1.
2. Garcia-Hernandez Mde L, Gray A, Hubby B, Kast WM. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res 2007;67:1344-1351
3. Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C, Wang Z, Gleave ME. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res 2005;11:4905-4911 (Pubitemid 41557211)
4. Roden AC, Moser MT, Tri SD, Mercader M, Kuntz SM, Dong H, Hurwitz AA, McKean DJ, Celis E, Leibovich BC, Allison JP, Kwon ED. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol 2004;173:6098-6108
5. Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature 2000;407:784-788 (Pubitemid 30780741)
6. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, Ellis TM, Wojcik EM, Yang D, Flanigan RC, Waters WB, Kast WM, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA 2001;98:14565-14570 (Pubitemid 33121432)
7. Matzinger P. Tolerance, danger, and the extended family. Ann Rev Immunol 1994;12:991-1045.
8. McBride WH, Chiang CS, Olson JL, Wang CC, Hong JH, Pajonk F, Dougherty GJ, Iwamoto KS, Pervan M, Liao YP. A sense of danger from radiation. Radiat Res 2004;162:1-19.
9. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004;64:7985-7994 (Pubitemid 39446933)
10. Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003;170:6338-6347 (Pubitemid 36682620)
11. Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002;8:1765-1780
12. Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 2005;63:655-666 (Pubitemid 41400049)
13. Nesslinger NJ, Sahota RA, Stone B, Johnson K, Chima N, King C, Rasmussen D, Bishop D, Rennie PS, Gleave M, Blood P, Pai H, et al. Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res 2007;13:1493-1502 (Pubitemid 46450440)
14. Miyake H, Nelson C, Rennie PS, Gleave ME. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000;60:170-176 (Pubitemid 30058748)
15. Minesita T, Yamaguchi K. An androgen-dependent mouse mammary tumor. Cancer Res 1965;25:1168-1175
16. Rennie PS, Bruchovsky N, Akakura K, Goldenberg SL, Otal N, Akakura S, Wong P, Tenniswood M. Effect of tumour progression on the androgenic regulation of the androgen receptor. TRPM-2 and YPT1 genes in the. Shionogi carcinoma. J Steroid Biochem Mol Biol 1994;50:31-40. (Pubitemid 24230492)
17. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990;50:2275-2282 (Pubitemid 20134481)
18. Skov K, Adomat H, Bowden M, Dragowska W, Gleave M, Koch CJ, Woo J, Yapp DT. Hypoxia in the androgen-dependent Shionogi model for prostate cancer at three stages. Radiat Res 2004;162:547-553 (Pubitemid 39600543)
19. Shmueli O, Horn-Saban S, Chalifa-Caspi V, Shmoish M, Ophir R, Benjamin-Rodrig H, Safran M, Domany E, Lancet D. GeneNote: whole genome expression profiles in normal human tissues. C R Biol 2003;326:1067-1072 (Pubitemid 38016462)
20. Lieberman J. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol 2003;3:361-370 (Pubitemid 37323196)
21. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949 (Pubitemid 39273735)
22. Torlakovic E, Slipicevic A, Robinson C, DeCoteau JF, Alfsen GC, Vyberg M, Chibbar R, Florenes VA. Pax-5 expression in nonhematopoietic tissues. Am J Clin Pathol 2006;126:798-804.
23. Winter SF, Sekido Y, Minna JD, McIntire D, Johnson BE, Gazdar AF, Carbone DP. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. J Natl Cancer Inst 1993;85:2012-2018 (Pubitemid 24000985)
24. Bergquist M, Brattstrom D, Larsson A, Holmertz J, Hesselius P, Rosenberg L, Wagenius G, Brodin O. p53 auto-antibodies in non-small cell lung cancer patients can predict increased life expectancy after radiotherapy. Anticancer Res 1998;18:1999-2002. (Pubitemid 28344861)
25. Vogl FD, Frey M, Kreienberg R, Runnebaum IB. Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass. Br J Cancer 2000;83:1338-1343 (Pubitemid 30839120)
26. Yamazaki Y, Chiba I, Ishikawa M, Satoh C, Notani K, Ohiro Y, Totsuka Y, Mizuno S, Kitagawa Y. Serum p53 antibodies as a prognostic indicator in oral squamous cell carcinoma. Odontology 2008;96:32-37
27. Bergqvist AS, Bergqvist M, Brattstrom D, Hesselius P, Larsson A, Brodin O, Wagenius G. Serum p53 autoantibodies as prognostic marker in patients with oesophageal carcinoma. Anticancer Res 2001;21:4141-4145 (Pubitemid 34229301)
28. Gumus E, Erdamar S, Demirel G, Horasanli K, Kendirci M, Miroglu C. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients. Int J Urol 2004;11:1070-1077 (Pubitemid 40053006)
29. Mack U, Ukena D, Montenarh M, Sybrecht GW. Serum anti-p53 antibodies in patients with lung cancer. Oncol Rep 2000;7:669-674
30. Pallasch CP, Struss AK, Munnia A, Konig J, Steudel WI, Fischer U, Meese E. Autoantibodies against GLEA2 and PHF3 in glioblastoma: tumor-associated autoantibodies correlated with prolonged survival. Int J Cancer 2005;117:456-459 (Pubitemid 41429569)
31. Bachelot T, Ratel D, Menetrier-Caux C, Wion D, Blay JY, Berger F. Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome. Br J Cancer 2006;94:1066-1070
32. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709-718 (Pubitemid 43247141)
33. Satzger I, Meier A, Schenck F, Kapp A, Hauschild A, Gutzmer R. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha. Int J Cancer 2007;121:2562-2566 (Pubitemid 350022429)
34. Xue LJ, Su QS, Yang JH, Lin Y. Autoimmune responses induced by Helicobacter pylori improve the prognosis of gastric carcinoma. Med Hypotheses 2008;70:273-276 (Pubitemid 350297628)
35. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24-37. (Pubitemid 43053650)
36. Shah S, Divekar AA, Hilchey SP, Cho HM, Newman CL, Shin SU, Nechustan H, Challita-Eid PM, Segal BM, Yi KH, Rosenblatt JD. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer 2005;117:574-586 (Pubitemid 41504545)
37. Inoue S, Leitner WW, Golding B, Scott D. Inhibitory effects of B cells on antitumor immunity. Cancer Res 2006;66:7741-7747 (Pubitemid 44289234)
38. Nakamoto Y, Kaneko S. Mechanisms of viral hepatitis induced liver injury. Curr Mol Med 2003;3:537-544 (Pubitemid 37173383)
39. Lundin BS, Enarsson K, Kindlund B, Lundgren A, Johnsson E, Quiding-Jarbrink M, Svennerholm AM. The local and systemic T-cell response to Helicobacter pylori in gastric cancer patients is characterised by production of interleukin-10. Clin Immunol 2007;125:205-213 (Pubitemid 47570111)
40. Sutherland JS, Goldberg GL, Hammett MV, Uldrich AP, Berzins SP, Heng TS, Blazar BR, Millar JL, Malin MA, Chidgey AP, Boyd RL. Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol 2005;175:2741-2753
41. Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci 2007;12:4957-4971
42. Drake CG, Doody AD, Mihalyo MA, Huang CT, Kelleher E, Ravi S, Hipkiss EL, Flies DB, Kennedy EP, Long M, McGary PW, Coryell L, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005;7:239-249 (Pubitemid 40568683)
43. Karja V, Aaltomaa S, Lipponen P, Isotalo T, Talja M, Mokka R. Tumour-infiltrating lymphocytes: a prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res 2005;25:4435-4438 (Pubitemid 41729492)
44. Kuhn U, Wahle E. Structure and function of poly(A) binding proteins. Biochem Biophys Acta 2004;1678:67-84. (Pubitemid 38626168)
45. Hosoda N, Lejeune F, Maquat LE. Evidence that poly(A) binding protein C1 binds nuclear pre-mRNA poly(A) tails. Mol Cell Biol 2006;26:3085-3097
46. Savage PA, Vosseller K, Kang C, Larimore K, Riedel E, Wojnoonski K, Jungbluth AA, Allison JP. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science 2008;319:215-220